BIIB34:BVMF
Biogen Inc BDR
184,49Â R$
0,00%
(0,00) 1K
5-okt, 15:59:13 (GMT-3) · BRL
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoBIIB34 tikeri uchun statistika yaratilmoqda...
Bozor kapitali
32,82Â mlrd
Oʻrtacha hajm
7,00
Hajmi
0,00
52 haftalik eng yuqori
191,00Â R$
52 haftalik eng past
128,69Â R$
Muomaladagi aksiyalar
147,75Â mln
Xodimlar soni
8Â ming
Bozor kapitali
32,82Â mlrd
Oʻrtacha hajm
7,00
Hajmi
0,00
52 haftalik eng yuqori
191,00Â R$
52 haftalik eng past
128,69Â R$
Muomaladagi aksiyalar
147,75Â mln
Xodimlar soni
8Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Simply Wall Street
·
3 soat oldin
How Positive Lupus Trial Data Will Impact Biogen Stock (BIIB)
AD HOC NEWS
·
1 kun oldin
Biogen stock heads toward October 28 results after 1.69 percent gain
Pluang
·
1 kun oldin
Biogen expected to slightly beat Q3 earnings wi...
Profil
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Biogen Inc BDR haqida
CEOChris Viehbacher
Xodimlar soni7,5Â ming
Asos solingan1978
Bosh ofislarKembrij, Massachusetts, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytbiogen.com